References
- Lowe G. D.O. Pathophysiology of critical leg ischemia. Critical leg ischemia, its pathophysiology and management, J A. Dormandy, G Stock. Springer-Verlag, Berlin 1990; 17–38
- Johnson M, Harrison H E., Raftery A T., Elder J B. Vascular prostacyclin may be reduced in diabetes in man. Lancet 1979; 1: 325–326
- Silberbauer K, Scherntahner G, Sinzinger H, Pizu-Katzer H, Winter M. Decreased vascular prostacyclin in juvenile-onset diabetes. N Engl J Med 1979; 300: 366–367
- Sinzinger H, Rogatti W, Prostaglandin E. atherosclerosis. Springer-Verlag, Berlin 1986; 3–109
- Steer M L., Salzman E W. Cyclic nucleotides in hemostasis and thrombosis. Adv Cyclic Nucleotide Protein Phosphorylation Res 1980; 12: 71–92
- Weksler B B. Prostacyclin. Prog Hemost Thromb 1982; 6: 113–138
- Modesti P A., Fortini A, Gensini G F., Vanni P, Prisco D, Abbate R. Human prostacyclin platelet receptors in diabetes mellitus. Thromb Res 1991; 63: 541–548
- Gasser J A., Cooper M B., Tan K C., Saggerson E P., Betteridge D J. Altered cellular signalling and decreased platelet sensitivity to adenosine in insulin-dependent diabetic patients with proliferative retinopathy. Cell Signal 1993; 5: 145–153
- Collier A, Tymkewycz P, Armstrong R., Young R J., Jones R L., Clarke B F. Increased platelet thromboxane receptor sensitivity in diabetic patients. Diabetologia 1986; 29: 471–474
- Dan G, Rimi G B., Averna M, et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin independent diabetics. Thromb Res 1982; 26: 359–370
- Betteridge D J., ElTahir K. E.H., Mess J. P.D., Williams K J. Platelets from diabetic subjects show diminished sensitivity to prostaglandins. Eur J Clin Invest 1982; 12: 395–398
- Pillay P K., Pillay U, Bulasubsumanian P, Lee K O. Platelet sensitivity to prostacyclin in diabetes mellitus. Ann Acad Med Singapore 1985; 14: 229–231
- Zahavi J, Zahavi M. Enhanced platelet release reaction, shortened platelet survival time and increased platelet aggregation and plasma thromboxane B2 in chronic obstructive arterial disease. Thromb Haemost 1985; 53: 105–109
- Banga J D., Sixma J J. Diabetes mellitus, vascular disease and thrombosis. Clin Haematol 1986; 15: 465–492
- Gilman A G. Proteins and regulation of adenyl-cyclase. JAMA 1989; 262: 1819–1825
- Zahavi J, Kakkar V V. P-thromboglobulin - a specific marker of in vivo platelet release reaction. Thromb Haemostas 1980; 44: 23–29
- DeGaetano G, Bertele V, Cerletti C. Mechanism of action and clinical use of prostanoids. Critical leg ischeia, its pathophysiology and management, J. A. Dormandy, G Stock. Springer-Verlag, Berlin 1990; 117–137
- Zahavi M, Zahavi J, Schafer R., Firsteter E, Laniado S. Abnormal typical pattern of platelet function and thromboxane generation in unstable angina. Thromb Haemostas 1989; 62: 840–845
- Zahavi M, Zahavi J, Kakkar V V. Effect of adenyl cyclase activators phosphodiesterase inhibitors and pyridoxal-5–phosphate on platelet aggregation and adenosine-3′5′ cyclic monophosphate accumulation. Thromb Haemostas 1984; 52: 205–209
- Brown B L., Albano J. D.M., Ekins R P., Scherzi A M. A simple and sensitive saturation assay for the measurement of adenosine-3′5′-monophosphate. Biochem J 1971; 121: 561–562
- Siegel S. Nonparametric statistics for the behavioral sciences. McGraw-Hill Kogakusha, Ltd, Tokyo 1956
- Gorman R R., Fitzpatrick F A., Miller O V. Reciprocal regulation of human platelet c-AMP levels and thromboxane B2 and prostacyclin. Adv Cyclic Nucleotide Protein Phosphorylation Res 1978; 9: 591–609
- Livingstone C., McGregor M A., et al. Altered G-protein expression and adenylate cyclase activity in platelets of non insulin-dependent diabetic (NIDDM) male subjects. Biochem Biophys Acta 1991; 1096: 127–133
- Haslam R J., Davidson M. M.L., Davies T, Lynham J A., McLenaghan M D. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucleotide Protein Phosphorylation Res 1978; 9: 533–552
- Silver P J., Walus K, DiSalvo J. Adenosine-mediated relaxation and activation of cyclic AMP-dependent protein kinase in coronary arterial smooth muscle. J Pharmacol Exp Ther 1984; 228: 342–347
- Lalli E, Sassone-Corsi P. Signal transduction and gene-regulation: The nuclear response to CAMP. J Biol Chem 1994; 269: 17359–17362
- Peterson S N., Lapetina E G. Platelet activation and inhibition. Novel signal transduction mechanisms. Acad Sci, New York 1994; 714: 53–63, Annals
- Hohlfeld T, Scharnowski F, Braun M, Schror K. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. Thromb Haemos 1994; 71: 112–118, t